

RESEARCH MONOGRAPH . COMPOUND PROFILE

EPI-743

A synthetic vitamin E-derived para-benzoquinone developed by Edison Pharmaceuticals as a potent inhibitor of 15-lipoxygenase and augments of intracellular glutathione biosynthesis, advanced through clinical evaluation in Leigh syndrome, Leber hereditary optic neuropathy, Friedreich ataxia, and other inherited mitochondrial respiratory chain diseases.

DOCUMENT	KDC-MN-1468
ISSUED	2026-05-13
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	Para-benzoquinone 15-lipoxygenase inhibitor and redox-active cytoprotectant derived from alpha-tocotrienol quinone

ABSTRACT

EPI-743, now designated vatiquinone (INN) and previously referred to by the development codes PTC-743 and alpha-tocotrienol quinone, is a synthetic para-benzoquinone derived from the chromanone ring system of vitamin E (alpha-tocotrienol) that was identified in a phenotypic screen for small molecules capable of preventing oxidative cell death induced by L-buthionine-(S,R)-sulfoximine (BSO), an irreversible inhibitor of gamma-glutamylcysteine synthetase and therefore of de novo glutathione biosynthesis. The compound is approximately 1,000- to 10,000-fold more potent than coenzyme Q10 or idebenone in protecting mitochondrial disease and Friedreich ataxia patient fibroblasts in oxidative stress assays, a potency differential attributed to its capacity to serve as a substrate for NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) and thereby to replenish reduced intracellular glutathione and stabilize cellular redox balance. The mechanistic target has subsequently been identified as 15-lipoxygenase (15-LO), an oxidoreductase enzyme that catalyzes the peroxidation of polyunsaturated fatty acids under conditions of glutathione depletion or glutathione peroxidase 4 (GPX4) inactivation, a process now recognized as the lipid peroxidation arm of ferroptotic cell death. Vatiquinone is therefore classified as a first-in-class selective inhibitor of 15-lipoxygenase with secondary redox-modulatory activity through NQO1-dependent glutathione replenishment. The compound was discovered at Edison Pharmaceuticals (Mountain View, California), a company founded by Guy Miller and subsequently renamed BioElectron Technology Corporation in 2017. PTC Therapeutics acquired substantially all

of BioElectron's assets, including the vatiquinone program, in October 2019 for approximately \$210 million. The clinical development program has spanned multiple inherited mitochondrial diseases and related conditions characterized by oxidative stress, mitochondrial dysfunction, and ferroptotic cell death. Open-label and emergency-protocol studies conducted between 2011 and 2017 evaluated EPI-743 in Leigh syndrome (Martinelli et al. 2012, ten pediatric patients, statistically significant reversal of disease progression on the Newcastle Pediatric Mitochondrial Disease Scale), in Leber hereditary optic neuropathy (Sadun et al. 2012, five patients, arrest of disease progression and reversal of visual loss in four of five subjects), in a heterogeneous cohort of genetically confirmed mitochondrial respiratory chain diseases (Enns et al. 2012, fourteen patients, clinical improvement in eleven of twelve survivors), and in Pearson syndrome. A Phase 2 study in Friedreich ataxia demonstrated safety and tolerability over two years. The pivotal registration-directed program is the Phase 3 MOVE-FA trial, a randomized, placebo-controlled, 72-week study in 146 pediatric and adult patients with Friedreich ataxia. The trial did not meet its primary endpoint of statistically significant change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS) in the primary analysis population ($p = 0.14$), though statistically significant effects were observed on the pre-specified upright stability subscale ($p = 0.021$) and in the per-protocol population ($p < 0.05$). Long-term extension data demonstrated a 3.7-point benefit on mFARS relative to a matched natural history cohort from the FACOMS disease registry at 144 weeks, representing a 50 percent slowing of disease progression over three years. PTC Therapeutics submitted a New Drug Application to the United States Food and Drug Administration, which granted Priority

Review with a PDUFA target action date of August 19, 2025. The FDA subsequently issued a Complete Response Letter, indicating that additional efficacy data would be required to support approval. Pharmacokinetics are characterized by oral absorption with an effective half-life of approximately 9 hours, dose-proportional exposure across oral doses of 200 to 1,400 mg, CYP3A4-mediated hepatic metabolism, and lipophilic distribution consistent with the vitamin E-derived chemical structure. The compound is administered three times daily with food to enhance bioavailability. The safety profile across more than 500 patients and treatment durations of up to 10 years is favorable, with no treatment-related serious adverse events reported in key long-term studies. This monograph reviews the chemistry, synthesis, and structural pharmacology of EPI-743; the 15-lipoxygenase inhibition and NQO1-dependent redox mechanism in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across Leigh syndrome, Leber hereditary optic neuropathy, Friedreich ataxia, and other mitochondrial diseases; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative mitochondrial cytoprotectant or antioxidant compounds (idebenone, omaveloxolone, coenzyme Q10, elamipretide, and alpha-tocopherol) against EPI-743 on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Vatiquinone.

Development codes: EPI-743 (Edison Pharmaceuticals), PTC-743 (PTC Therapeutics). The development code EPI-743 is the canonical identifier in the early clinical literature and the only identifier under which the seminal Enns et al. (2012) and Martinelli et al. (2012) mitochondrial disease studies were published [1, 2].

Marketed names: The compound has not been approved for marketing in any jurisdiction as of the most recent monograph revision. There is no branded trade name.

Chemical Abstracts Service registry number: 1213269-98-7.

International Union of Pure and Applied Chemistry name: 2-[(3R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl]-3,5,6-trimethylcyclohexa-3,6-diene-1,4-dione. The compound is the para-benzoquinone (cyclohexadienedione) oxidized form of alpha-tocotrienol, bearing the intact isoprenoid side chain with its three trans-configured double bonds and a tertiary hydroxyl group at the 3-position.

Other synonyms: Alpha-tocotrienol quinone, alpha-TQ.

1.2 Structural class and chemistry

EPI-743 is a para-benzoquinone, a subclass of the broader quinone family that includes ubiquinone (coenzyme Q10), idebenone, and menadione. The structural class is defined by the 1,4-cyclohexadienedione ring, which undergoes reversible two-electron reduction to the corresponding hydroquinone (the reduced chromanone form). This redox cycling is the molecular basis for the compound's function as a substrate for NQO1 and as a participant in intracellular electron transfer [3].

Molecular formula: C₂₉H₄₄O₃.

Exact mass: 440.3290 g/mol (monoisotopic).

Molecular weight: 440.66 g/mol.

Physical properties: Yellow to orange crystalline or amorphous solid. Lipophilic, consistent with the isoprenoid side chain. Soluble in organic solvents including dimethyl sulfoxide, ethanol, and chloroform; sparingly soluble in water. The compound's lipophilicity contributes to its tissue distribution and to the requirement for administration with food to enhance oral bioavailability.

Stereochemistry: The compound contains one defined stereocenter at carbon 3 of the isoprenoid side chain in the (R)-configuration and three trans (E)-configured double bonds in the geranylgeraniol-derived side chain. The (3R) configuration is the naturally occurring form shared with alpha-tocotrienol.

1.3 Synthesis

EPI-743 is a synthetic compound produced by chemical oxidation of naturally derived or synthetic alpha-tocotrienol. The published synthetic approach involves controlled chromatic ring opening and oxidation of alpha-tocotrienol to the corresponding para-benzoquinone using reagents such as ceric ammonium nitrate, silver(I) oxide, or Fremy's salt (potassium nitrosodisulfonate) [4]. The quinone product is purified by column chromatography (silica gel, hexane/ethyl acetate gradient) or by preparative high-performance liquid chromatography and characterized by nuclear magnetic resonance spectroscopy (¹H and ¹³C), high-resolution mass spectrometry, and HPLC area-percent purity analysis. Industrial-scale production optimizes the oxidation step for yield and for minimization of over-oxidation byproducts. The compound is manufactured in greater than 98 percent chemical purity for pharmaceutical and research applications.

2. Abstract

EPI-743 (vatiquinone, PTC-743, alpha-tocotrienol quinone) is a first-in-class selective inhibitor of 15-lipoxygenase (15-LO) and a redox-active para-benzoquinone derived from vitamin E (alpha-tocotrienol) that augments intracellular glutathione biosynthesis through its function as a substrate for NAD(P)H:quinone oxidoreductase 1 (NQO1) [3, 5]. The compound was identified in a phenotypic screen at Edison Pharmaceuticals for small molecules preventing cell death induced by the glutathione synthesis inhibitor L-buthionine-(S,R)-sulfoximine and was found to be approximately 1,000- to 10,000-fold more potent than coenzyme Q10 or idebenone in protecting mitochondrial disease patient fibroblasts from oxidative stress [1].

The mechanistic target was subsequently identified as 15-lipoxygenase, an enzyme that drives iron-catalyzed lipid peroxidation when glutathione levels are low or when glutathione peroxidase 4 (GPX4) is inactivated, a process now understood as the lipid peroxidation arm of ferroptotic cell death [5, 6]. The dual mechanism of 15-LO inhibition and NQO1-dependent glutathione replenishment distinguishes EPI-743 from other quinone-based mitochondrial therapeutics (idebenone, coenzyme Q10) that function primarily as electron carriers in the mitochondrial respiratory chain.

The clinical development program has evaluated EPI-743 across a range of inherited mitochondrial diseases and conditions characterized by mitochondrial dysfunction and oxidative stress. The earliest clinical data came from emergency and compassionate use protocols. Enns et al. (2012) reported on fourteen patients with genetically confirmed mitochondrial disease (polymerase gamma deficiency, Leigh syndrome, MELAS, mitochondrial DNA deletion syndrome, Friedreich ataxia) treated in an open-label, subject-controlled study; eleven of twelve surviving patients demonstrated clinical improvement, and HMPAO SPECT brain imaging correlated with clinical response [1]. Martinelli et al. (2012) reported a Phase 2A study of ten consecutive children with genetically defined Leigh syndrome treated for six months; all children exhibited reversal of disease progression with statistically significant improvement on the Newcastle Pediatric Mitochondrial Disease Scale, the Gross Motor Function Measure, and the PedsQL Neuromuscular Module [2]. Sadun et al. (2012) evaluated EPI-743 in five patients with Leber hereditary optic neuropathy.

thy (LHON) treated within 90 days of visual conversion; four of five patients demonstrated arrest of disease progression and reversal of visual loss, with two patients achieving total recovery of visual acuity [7].

The most advanced clinical program is the Phase 3 MOVE-FA trial in Friedreich ataxia, a randomized, double-blind, placebo-controlled, 72-week study in 146 pediatric and adult patients. The trial did not meet its primary endpoint of statistically significant change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS) in the primary analysis population ($p = 0.14$), though pre-specified secondary analyses demonstrated significant effects on upright stability ($p = 0.021$) and the per-protocol population showed significance on the primary endpoint ($p < 0.05$) [8, 9]. Long-term extension data at 144 weeks demonstrated a 3.7-point benefit on mFARS relative to a matched natural history cohort, representing a clinically meaningful 50 percent slowing of disease progression [10]. The United States Food and Drug Administration accepted a New Drug Application for Priority Review but subsequently issued a Complete Response Letter indicating that additional efficacy data would be required for approval [11].

The compound is orally bioavailable, is administered three times daily with food, has an effective half-life of approximately 9 hours, and is metabolized predominantly by CYP3A4. The safety profile across more than 500 patients with treatment durations of up to 10 years is favorable, with no treatment-related serious adverse events reported in key long-term studies [9, 10]. The compound is not approved by any regulatory authority as of the most recent monograph revision. It is available as a research-grade preparation from chemical suppliers; investigators should confirm identity and purity on every lot.

3. Discovery and Development History

3.1 Origin

EPI-743 was discovered at Edison Pharmaceuticals, a company founded by Guy Miller, M.D., Ph.D., in Mountain View, California, with a mission to develop therapeutics for mitochondrial diseases. The discovery program was based on a phenotypic screen: a library of para-benzoquinone analogs derived from the vitamin E tocotrienol and tocopherol families was screened for the ability to prevent cell death in patient-derived fibroblasts exposed to L-buthionine-(S,R)-sulfoximine (BSO), an irreversible inhibitor of gamma-glutamylcysteine synthetase that depletes intracellular glutathione and induces oxidative cell death [1, 3]. EPI-743 emerged as the most potent compound in this screen, exceeding the protective activity of coenzyme Q10 and idebenone by three to four orders of magnitude in the BSO-induced death assay. The compound was selected for development on the basis of this potency, oral bioavailability, central nervous system penetration, and a favorable preliminary toxicology profile in rodents.

3.2 Early clinical development (2011 to 2013)

Edison Pharmaceuticals advanced EPI-743 rapidly into clinical evaluation through emergency and compassionate use protocols, enabled by the severe and progressive nature of the target diseases and by the absence of approved therapies. The first published clinical data appeared in 2012:

The Enns et al. (2012) open-label study enrolled thirteen children and one adult with genetically confirmed mitochondrial disease, including polymerase gamma deficiency (n = 4), Leigh syndrome (n = 4), MELAS (n = 3), mitochondrial DNA deletion syndrome (n = 2), and Friedreich ataxia (n = 1) [1]. Twelve patients survived (one patient with polymerase gamma deficiency died of pneumonia; one patient with Surf-1 deficiency died after protocol completion). Of the twelve survivors, eleven demonstrated clinical improvement, and ten had improvement in quality-of-life scores. HMPAO SPECT imaging showed increased regional and whole-brain uptake in clinical responders.

The Martinelli et al. (2012) Phase 2A study enrolled ten consecutive children aged 1 to 13 years with genetically defined Leigh syndrome across seven distinct genetic defects [2]. All children were treated with EPI-743 three times daily for six months. All ten demonstrated reversal of disease progression regardless of genetic determinant or disease severity, with statistically significant improvement on the Newcastle Pediatric Mitochondrial Disease Scale, the Gross Motor Function Measure, and the PedsQL Neuromuscular Module ($p < 0.05$ for each). No drug-related adverse events were observed.

The Sadun et al. (2012) study evaluated EPI-743 in five patients with genetically confirmed Leber hereditary optic neuropathy treated within 90 days of conversion to acute visual loss [7]. Four of five patients demonstrated arrest of disease progression and reversal of visual loss, with two patients achieving total recovery of visual acuity. A 2015 compassionate use update reported that EPI-743 improved vision by study criteria in 56 percent of treated eyes, with visual improvement observed up to four years after initiation [12].

Edison also initiated a clinical trial in Pearson syndrome and additional open-label studies in patients with mitochondrial DNA point mutations.

3.3 Corporate transitions

Edison Pharmaceuticals was renamed BioElectron Technology Corporation in 2017 [13]. In October 2019, PTC Therapeutics, Inc. (Nasdaq: PTCT) acquired substantially all of BioElectron's assets, including the EPI-743 development program, for approximately \$210 million. PTC redesignated the compound PTC-743 and advanced the Friedreich ataxia program as the lead registration-directed indication.

3.4 Friedreich ataxia development (2013 to present)

A Phase 2 clinical trial in adults with Friedreich ataxia was initiated by Edison Pharmaceuticals in 2013 through enrollment via the Friedreich's Ataxia Research Alliance (FARA) Patient Registry at three United States sites [14]. The Phase 2 trial demonstrated safety and tolerability over two years. Although the primary endpoint (a measure of visual function at six months) was not met, investigators observed trends toward improvement in neurological function, and subsequent analyses suggested meaningful gains relative to matched natural history data.

PTC Therapeutics initiated the Phase 3 MOVE-FA trial in January 2021, a registration-directed, randomized, double-blind, placebo-controlled, 72-week study evaluating vatiquinone (200 mg or 400 mg three times daily, administered with food) versus placebo in 146 children, adolescents, and young adults with Friedreich ataxia [8]. The primary endpoint was change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS), a clinical assessment that measures disease progression across domains of swallowing and speech, upper and lower limb coordination, and upright stability. The trial did not meet its primary endpoint in the primary analysis population (all enrolled patients aged 7 to 21 years, $N = 123$; $p = 0.14$). However, statistically significant effects were recorded on the pre-specified upright stability subscale ($p = 0.021$) and on the bulbar subscale ($p = 0.044$), and the per-protocol population demonstrated significance on the overall mFARS endpoint ($p < 0.05$), the upright stability subscale ($p < 0.026$), and the modified fatigue rating scale ($p < 0.042$). The placebo-corrected difference in mFARS in the per-protocol population was 2.31 points, representing a 75 percent slowing of disease progression over 72 weeks [9].

3.5 Regulatory outcome

PTC Therapeutics submitted a New Drug Application (NDA) to the United States Food and Drug Administration. The FDA accepted the NDA for filing, granted Priority Review, and assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 19, 2025. Long-term extension data from the MOVE-FA trial demonstrated that 144 weeks of vatiquinone treatment produced a 3.7-point benefit on mFARS relative to a matched natural history cohort from the FACOMS disease registry ($p < 0.0001$, $N = 70$), representing a clinically meaningful 50 percent slowing of disease progression over three years [10]. Despite these extension data, the FDA issued a Complete Response Letter in 2025, concluding that sufficient evidence of efficacy had not been demonstrated and that an additional clinical study would be required to support resubmission of the application [11].

3.6 Preclinical re-evaluation

A 2025 study by Stokes et al. evaluated vatiquinone in preclinical models of Leigh syndrome (Ndufs4 knockout mice) and GPX4 deficiency (tamoxifen-inducible GPX4 knockout mice) [15]. The study confirmed that vatiquinone robustly prevents ferroptosis in cultured cells treated with RSL3 or BSO combined with ferric citrate but reported no impact on disease onset, progression, or survival in either mouse

model, though the drug may have reduced seizure risk. The findings indicate that the anti-ferroptotic mechanism is confirmed in vitro but does not translate to survival benefit in these specific preclinical models of mitochondrial disease.

4. Mechanism of Action

EPI-743 is a multi-mechanism redox-active compound. Its principal molecular activities are inhibition of 15-lipoxygenase and NQO1-dependent augmentation of intracellular glutathione biosynthesis. These activities converge on the regulation of cellular redox balance, lipid peroxidation, and ferroptotic cell death, processes that are dysregulated in inherited mitochondrial respiratory chain diseases and in Friedreich ataxia.

4.1 15-Lipoxygenase inhibition

15-Lipoxygenase (15-LO, encoded by ALOX15 in humans) is a non-heme iron-containing dioxygenase that catalyzes the stereospecific peroxidation of polyunsaturated fatty acids, principally arachidonic acid and linoleic acid, to produce 15-hydroperoxyeicosatetraenoic acid (15-HpETE) and 13-hydroperoxyoctadecadienoic acid (13-HpODE). Under physiological conditions, these lipid hydroperoxides are reduced to their corresponding alcohols by glutathione peroxidase 4 (GPX4) using reduced glutathione as the electron donor [5, 6].

Under pathological conditions of glutathione depletion or GPX4 inactivation (as occurs in mitochondrial disease due to impaired respiratory chain function, elevated reactive oxygen species production, and consequent depletion of the glutathione pool), 15-LO-generated lipid hydroperoxides accumulate in cellular membranes, propagate lipid peroxidation through radical chain reactions, and trigger ferroptotic cell death. Ferroptosis is a form of regulated cell death characterized by iron-dependent lipid peroxidation, distinct from apoptosis, necroptosis, and autophagy [16].

EPI-743 inhibits 15-lipoxygenase selectively, preventing the enzymatic generation of lipid hydroperoxides that initiate the ferroptotic cascade. The inhibition is direct and does not require metabolic activation. This mechanism positions vaticquinone as a first-in-class anti-ferroptotic therapeutic acting upstream of lipid peroxidation, distinct from radical-trapping antioxidants (vitamin E, ferrostatin-1) that scavenge lipid radicals after their formation and distinct from iron chelators (deferiprone) that reduce iron availability for the Fenton reaction [5].

4.2 NQO1-dependent glutathione replenishment

NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase, EC 1.6.5.2) is a cytosolic flavoenzyme that catalyzes the obligatory two-electron reduction of quinone substrates to their corresponding hydroquinones, bypassing the one-electron semiquinone radical intermediate that generates superoxide in the mitochondrial respiratory chain [3]. The two-electron reduction of EPI-743 by NQO1 produces the corresponding hydroquinone (the reduced chromanone form), which is then available to participate in downstream reduction reactions that regenerate reduced glutathione from its oxidized form (GSSG) and that support the de novo biosynthesis of glutathione by maintaining the cellular thiol redox state.

The net effect is an NQO1-catalyzed amplification of intracellular reduced glutathione, the principal intracellular thiol antioxidant and the obligate cofactor for GPX4-mediated reduction of lipid hydroperoxides. By replenishing the glutathione pool, EPI-743 reinforces the endogenous defense against lipid peroxidation at a point downstream of the 15-LO inhibition, creating a dual blockade of the ferroptotic pathway: inhibition of the enzyme that generates the toxic lipid hydroperoxide (15-LO) and augmentation of the enzyme system that reduces it (GPX4, via glutathione supply) [3, 5].

4.3 Relationship to mitochondrial respiratory chain dysfunction

In inherited mitochondrial respiratory chain diseases (Leigh syndrome, MELAS, Leber hereditary optic neuropathy, polymerase gamma deficiency, Friedreich ataxia), defects in oxidative phosphorylation complexes I through V or in mitochondrial DNA maintenance produce elevated mitochondrial reactive oxygen species, depletion of NAD⁺ and NADH pools, secondary depletion of the glutathione pool, and progressive lipid peroxidation in mitochondrial and cellular membranes [17]. The clinical consequences include progressive neurodegeneration, optic neuropathy, cardiomyopathy, myopathy, and multisystem failure.

EPI-743 addresses this pathophysiology at the level of lipid peroxidation and glutathione depletion rather than at the level of the primary respiratory chain defect. The compound does not restore complex I, II, III, IV, or V activity; it does not increase electron transport chain throughput; and it does not function as an electron carrier within the mitochondrial inner membrane (unlike coenzyme Q10 and

idebenone, which serve as mobile electron carriers between complex I or II and complex III). Instead, it suppresses the downstream oxidative damage that is the proximate cause of cell death in these conditions [5, 15].

4.4 Composite pharmacology and selectivity

The composite pharmacology of EPI-743 at clinical doses (200 to 400 mg three times daily) produces systemic exposure (AUC) that increases proportionally with dose across the 200 to 1,400 mg range [18]. At these exposures, potent inhibition of 15-LO is achieved, and NQO1-dependent glutathione augmentation is engaged. The compound does not have characterized activity at conventional receptor targets (G protein-coupled receptors, ligand-gated ion channels, nuclear hormone receptors) and is not a kinase inhibitor. The selectivity for the 15-LO/NQO1/glutathione pathway distinguishes EPI-743 from broad-spectrum antioxidants (vitamin E, N-acetylcysteine) that scavenge reactive oxygen species non-selectively.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

EPI-743 is absorbed from the gastrointestinal tract after oral administration with food-dependent bioavailability. The compound is lipophilic, and oral absorption is enhanced by coadministration with meals containing moderate fat content (25 to less than 50 percent of calories from fat) [18, 19]. The absorption fraction through the first-order process is approximately 74.4 percent. A zero-order absorption component accounts for approximately 25.6 percent of absorption, with a duration of approximately 6 hours, reflecting the extended dissolution of the lipophilic compound in the gastrointestinal tract. The absorption rate constant is approximately 0.20 per hour, with a lag time of approximately 2.8 hours. Time to peak plasma concentration is variable and dependent on prandial state. Dose-proportional exposure (C_{max} and AUC) has been demonstrated across oral doses of 200 to 1,400 mg at Day 1 [18].

Patients with Friedreich ataxia exhibit a 50 percent reduction in relative bioavailability and a 40 percent decrease in clearance compared to healthy volunteers, producing comparable steady-state exposures at the same doses [18].

5.2 Distribution

EPI-743 has a large volume of distribution consistent with extensive tissue partitioning (apparent volume of distribution approximately 181 liters for the central compartment and approximately 4,853 liters for the peripheral compartment in a two-compartment model) [18]. The lipophilic character of the isoprenoid side chain drives accumulation in lipid-rich tissues including the central nervous system. The compound crosses the blood-brain barrier, a property critical for its activity in neurodegenerative mitochondrial diseases affecting the basal ganglia (Leigh syndrome) and the optic nerve (LHON). Plasma protein binding has not been reported in public-domain pharmacokinetic publications but is expected to be high given the lipophilicity.

5.3 Metabolism

EPI-743 is metabolized predominantly in the liver by cytochrome P450 3A4 (CYP3A4) [19, 20]. In an absorption, distribution, metabolism, and excretion (ADME) study using ¹⁴C-labeled vatiquinone in rats, dogs, and human subjects, the parent compound was the most prominent drug-related component in feces, and no plasma metabolites exceeded 10 percent of total drug-related exposure in any species [19]. Vatiquinone was not detectable in urine, indicating that renal excretion of the parent is negligible.

The CYP3A4 dependence has been characterized in formal drug-drug interaction studies. Coadministration of vatiquinone (400 mg) with the strong CYP3A4 inhibitor itraconazole (200 mg) increased vatiquinone C_{max} and AUC by approximately 3.5-fold and 2.9-fold, respectively [20]. Coadministration with the strong CYP3A4 inducer rifampin (600 mg) decreased vatiquinone C_{max} and AUC by approximately 36 percent and 46 percent, respectively. The terminal half-life was not materially affected by either itraconazole or rifampin. These data establish vatiquinone as a CYP3A4-sensitive substrate.

Vatiquinone does not have clinically relevant perpetrator effects on CYP2C9, CYP2C19, or breast cancer resistance protein (BCRP). A clinical drug-drug interaction study with rosuvastatin (a BCRP substrate) demonstrated no significant effect of clinical doses of vatiquinone on rosuvastatin exposure [21]. Physiologically based pharmacokinetic (PBPK) modeling confirmed the absence of clinically relevant CYP450 perpetrator risk [22].

5.4 Elimination

The effective half-life is approximately 9 hours, supporting a three-times-daily dosing regimen to maintain therapeutic drug exposures throughout the dosing interval [18]. Apparent clearance is approximately 163 liters per hour. Elimination is predominantly through fecal excretion of the parent compound and metabolites; renal excretion is negligible.

5.5 Routes of administration

The compound is administered orally. The clinical dosing regimen in Friedreich ataxia is 200 mg or 400 mg three times daily with food. In early mitochondrial disease studies, the dosing regimen was weight-based or titrated, administered orally

three times daily. No intravenous, intramuscular, or subcutaneous formulation has been developed for clinical use.

5.6 Special populations

Pediatric pharmacokinetics have been characterized, as the majority of MOVE-FA trial participants were under 18 years of age. The compound has been administered to children as young as 1 year of age in the Leigh syndrome studies [2]. Geriatric pharmacokinetics have not been formally characterized. Patients with Friedreich ataxia exhibit altered pharmacokinetics relative to healthy volunteers (reduced bioavailability, reduced clearance) that result in comparable steady-state exposures at the same doses [18]. Hepatic impairment would be expected to increase exposure given the CYP3A4-mediated metabolism; formal hepatic impairment studies have not been published.

6. Preclinical Pharmacology

6.1 In vitro oxidative stress models

EPI-743 was identified in a phenotypic screen for prevention of BSO-induced cell death in patient-derived fibroblasts from individuals with mitochondrial disease and Friedreich ataxia [1, 3]. In this assay, EPI-743 was approximately 1,000- to 10,000-fold more potent than coenzyme Q10 or idebenone. The protective effect correlated with augmentation of intracellular reduced glutathione as measured by monochlorobimane fluorescence and by enzymatic glutathione cycling assays.

6.2 Ferroptosis models

Vatiquinone robustly prevents ferroptotic cell death in human fibroblasts and HEK293 cells treated with RSL3 (a direct GPX4 inhibitor) or with the combination of BSO and ferric citrate [15]. The compound does not prevent cell death induced by paraquat (a mitochondrial complex I inhibitor and superoxide generator) or by rotenone (a complex I inhibitor), indicating specificity for the lipid peroxidation arm of oxidative cell death rather than general protection against mitochondrial electron transport chain inhibition [15].

6.3 Animal models

In the *Ndufs4* knockout mouse model of Leigh syndrome, vatiquinone had no impact on disease onset, progression, or survival, though the drug may have reduced seizure risk [15]. In the tamoxifen-inducible GPX4 knockout mouse model, vatiquinone similarly did not affect disease onset, progression, or survival [15]. These negative preclinical findings, published in 2025, contrast with the positive open-label clinical data from the Martinelli et al. (2012) Leigh syndrome study and have implications for the interpretation of the clinical evidence base and for drug trial design in rare mitochondrial diseases.

7. Clinical Evidence Base

7.1 Inherited mitochondrial respiratory chain diseases

The Enns et al. (2012) study enrolled thirteen children and one adult with genetically confirmed mitochondrial respiratory chain diseases in a subject-controlled, open-label, 13-week emergency treatment protocol [1]. Genetic diagnoses included polymerase gamma (POLG) deficiency (n = 4), Leigh syndrome (n = 4), MELAS (n = 3), mitochondrial DNA deletion syndrome (n = 2), and Friedreich ataxia (n = 1). Twelve patients survived; two patients died (one POLG patient from pneumonia, one Surf-1 deficiency patient after protocol completion). Of the twelve survivors, eleven demonstrated clinical improvement, and ten had improvement in quality-of-life scores. HMPAO SPECT brain imaging correlated with clinical response: increased regional and whole-brain HMPAO uptake was observed in clinical responders, while the one non-responding patient showed decreased uptake. The study concluded that EPI-743 modified disease progression in more than 90 percent of patients as assessed by clinical, quality-of-life, and non-invasive brain imaging parameters.

7.2 Leigh syndrome

The Martinelli et al. (2012) Phase 2A study is the principal published trial in Leigh syndrome [2]. Ten consecutive children aged 1 to 13 years with genetically defined Leigh syndrome spanning seven different genetic defects were treated with EPI-743 three times daily for six months. All ten children demonstrated reversal of disease progression. Primary endpoints (Newcastle Pediatric Mitochondrial Disease Scale, Gross Motor Function Measure, PedsQL Neuromuscular Module) all showed statistically significant improvement ($p < 0.05$). No drug-related adverse events were recorded.

A Japanese case report (Yamada et al. 2017) documented treatment of a Leigh syndrome patient with EPI-743 [23]. The report noted clinical improvement consistent with the Martinelli et al. findings, though the single-patient design limits generalizability.

The 2025 preclinical study by Stokes et al. using the Ndufs4 knockout mouse model of Leigh syndrome did not replicate the survival benefit observed in clinical studies [15]. The discordance between the positive open-label clinical data and the negative preclinical model data remains unexplained and may reflect differences in disease mechanism, drug exposure, or outcome measure sensitivity between the human clinical setting and the Ndufs4 knockout model.

7.3 Leber hereditary optic neuropathy

Sadun et al. (2012) evaluated EPI-743 in five patients with genetically confirmed Leber hereditary optic neuropathy (LHON) enrolled within 90 days of conversion to acute visual loss [7]. Four of five patients demonstrated arrest of disease progression and reversal of visual loss. Two patients achieved total recovery of visual acuity. No drug-related adverse events were recorded. The publication was in JAMA Neurology (Archives of Neurology at time of publication).

A 2015 update of the ongoing compassionate use study reported that EPI-743 improved vision by study criteria in 56 percent of treated eyes, with visual improvement observed up to four years after initiation of therapy [12]. A Brazilian compassionate use cohort extended these observations. The LHON evidence base for EPI-743, though small, represents the most consistent signal of clinical benefit, as the natural history of acute LHON conversion is progressive and frequently permanent visual loss in the absence of intervention.

7.4 Friedreich ataxia

Friedreich ataxia (FA) is a progressive neurodegenerative disease caused by biallelic GAA trinucleotide repeat expansions in the FXN gene, resulting in reduced expression of the mitochondrial protein frataxin. Frataxin deficiency leads to impaired iron-sulfur cluster biosynthesis, mitochondrial iron accumulation, oxidative stress, and progressive degeneration of dorsal root ganglia, spinocerebellar tracts, and cardiomyocytes [24].

The rationale for vaticquinone in Friedreich ataxia is based on the shared downstream pathophysiology of glutathione depletion and lipid peroxidation. The compound does not address the primary frataxin deficiency but targets the oxidative damage that is the proximate cause of neuronal and cardiac cell death.

Phase 2

Edison Pharmaceuticals initiated a Phase 2 clinical trial in adults with Friedreich ataxia in 2013 at three United States sites [14]. The trial demonstrated safety and tolerability over a two-year treatment period. The primary endpoint (a measure of visual function at six months) was not met. Post hoc analyses suggested trends toward improvement in neurological function relative to matched natural history data.

Phase 3 MOVE-FA

PTC Therapeutics initiated the Phase 3 MOVE-FA trial in January 2021 [8, 9]. The trial was a randomized, double-blind, placebo-controlled, parallel-arm, 72-week study enrolling 146 patients (the majority under 18 years of age) at multiple sites. The primary analysis population comprised all enrolled patients aged 7 to 21 years (N = 123). The primary endpoint was change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS), a clinical assessment that measures swallowing and speech, upper and lower limb coordination, and upright stability.

Primary outcome: The trial did not meet its primary endpoint ($p = 0.14$ in the primary analysis population).

Pre-specified secondary outcomes with nominal significance: Upright stability subscale of mFARS ($p = 0.021$); bulbar subscale of mFARS ($p = 0.044$).

Per-protocol population: In the population that completed the study protocol, the overall mFARS endpoint reached significance ($p < 0.05$), as did the upright stability subscale ($p < 0.026$) and the modified fatigue rating scale ($p < 0.042$). The placebo-corrected difference in mFARS was 2.31, representing a 75 percent slowing of disease progression over 72 weeks [9].

Long-term extension

Analysis of the MOVE-FA long-term extension study demonstrated that 144 weeks (approximately three years) of vatiquinone treatment resulted in a 3.7-point benefit on mFARS relative to a matched natural history cohort from the Friedreich Ataxia Clinical Outcome Measures Study (FACOMS) registry ($p < 0.0001$, N = 70), representing a 50 percent slowing of disease progression [10].

Regulatory outcome

The FDA accepted the NDA for Priority Review with a PDUFA target action date of August 19, 2025. The FDA subsequently issued a Complete Response Letter indicating that an additional study would be needed to support a resubmission [11]. The compound is not approved for the treatment of Friedreich ataxia.

7.5 Other mitochondrial diseases

EPI-743 has been evaluated in Pearson syndrome (an open-label study initiated by Edison Pharmaceuticals) and in patients with mitochondrial DNA point mutations [13, 25]. Published data from these studies are limited; the available evidence supports safety and tolerability but does not permit efficacy conclusions owing to the small sample sizes and open-label designs.

Enns and Cohen (2017) provided a comprehensive review of EPI-743 and RP103 (cysteamine bitartrate) clinical trials in mitochondrial disease, cataloging the breadth of the clinical development program [25].

8. Sourcing and Quality Verification

EPI-743 (vatiquinone) is not available as a marketed pharmaceutical product, as the compound has not received regulatory approval in any jurisdiction. The compound is therefore sourced exclusively from research chemical suppliers for investigational and research applications.

Research-grade vatiquinone is supplied by multiple chemical and pharmaceutical research suppliers (Cayman Chemical, MedChemExpress, Selleckchem, AbMole BioScience, GlpBio, InvivoChem, MedKoo Biosciences, others) at greater than 98 percent purity by HPLC. Supply is available in milligram to gram quantities. Pricing varies by supplier and quantity but is generally in the range of \$100 to \$500 per 100 mg at the time of monograph preparation.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- High-resolution mass spectrometry confirmation of molecular weight (441.3369 for the protonated molecular ion $[M+H]^+$)
- Nuclear magnetic resonance spectroscopy (1H and ^{13}C) confirmation of structure, including verification of the (3R) stereocenter and the three (E)-configured olefins
- Karl Fischer or loss-on-drying analysis for residual water
- Assessment of enantiomeric and geometric isomeric purity

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. Given the lipophilic nature of the compound and its susceptibility to oxidation, lot-to-lot variability in the hydroquinone-to-quinone ratio is possible, and on-receipt analytical confirmation is appropriate for any investigation where dose-response precision is important.

9. Reconstitution and Handling

EPI-743 is a lipophilic solid that is sparingly soluble in water. For in vitro research applications, stock solutions are typically prepared in dimethyl sulfoxide (DMSO) at concentrations of 10 to 100 mM. The compound is also soluble in ethanol, methanol, and chloroform. Aqueous dilutions from DMSO stock solutions should maintain the DMSO concentration below 0.1 percent (v/v) for cell-based assays to avoid solvent cytotoxicity.

Storage of the solid compound should be at minus 20 degrees Celsius, protected from light and moisture. The para-benzoquinone ring system is susceptible to reduction to the hydroquinone form under ambient conditions; light protection and storage under inert atmosphere (nitrogen or argon) are recommended for long-term storage of research-grade material.

DMSO stock solutions are stable at minus 20 degrees Celsius for at least six months when protected from light. Repeated freeze-thaw cycles should be minimized; aliquoting into single-use volumes at the time of stock preparation is recommended.

For in vivo research applications (rodent dosing), the compound is typically formulated in a vehicle containing a solubilizing agent (polyethylene glycol 400, Cremophor EL, or cyclodextrin-based systems) combined with a suspending agent (methylcellulose, carboxymethylcellulose) to achieve adequate oral bioavailability. The clinical oral formulation was a capsule, with the recommendation to administer with food containing moderate fat content to enhance absorption [18].

10. Stack Interactions and Combinations

Investigators conducting research with EPI-743, particularly in chronic dosing regimens or in combination with other compounds, should consider the following pharmacokinetic and pharmacodynamic interactions:

CYP3A4 inhibitors: Strong inhibitors (itraconazole, ketoconazole, ritonavir, clarithromycin, grapefruit juice) substantially increase vatiquinone exposure (up to 3.5-fold increase in Cmax with itraconazole) [20]. Concurrent use requires dose adjustment or avoidance.

CYP3A4 inducers: Strong inducers (rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort) decrease vatiquinone exposure by approximately 36 to 46 percent [20]. Concurrent use may reduce efficacy.

Other quinone-based compounds: Concurrent use with coenzyme Q10 or idebenone is pharmacologically redundant for the NQO1-dependent redox mechanism, as all three compounds serve as NQO1 substrates. However, coenzyme Q10 and idebenone additionally function as electron carriers in the mitochondrial respiratory chain (a mechanism EPI-743 does not share), so the combination may have additive effects through non-overlapping mechanisms. The combination has not been formally studied.

Iron chelators: Concurrent use with deferiprone, deferoxamine, or deferasirox addresses the same ferroptotic pathway through complementary mechanisms (iron chelation versus 15-LO inhibition) and is theoretically additive. The combination has been explored conceptually for Friedreich ataxia but has not been formally evaluated in clinical studies.

Omaveloxolone (Skyclarys): As an Nrf2 activator approved for Friedreich ataxia, omaveloxolone addresses oxidative stress through a different mechanism (upregulation of endogenous antioxidant gene expression). The combination with vatiquinone has not been studied but is of theoretical interest given the complementary mechanisms.

Statins: Clinical drug-drug interaction studies demonstrate that vatiquinone does not significantly affect rosuvastatin exposure (a BCRP substrate) [21]. No dose adjustment is required for concurrent statin use.

N-acetylcysteine: As a direct precursor to glutathione biosynthesis, N-acetylcysteine addresses the glutathione depletion pathway through a mechanism complementary to the NQO1-dependent glutathione replenishment of vatiquinone. The combination is theoretically additive but has not been formally evaluated.

11. Adverse Events and Safety

11.1 Common adverse events

The safety profile of EPI-743 across its clinical development program is consistently favorable. In the early open-label mitochondrial disease studies (Enns et al. 2012, Martinelli et al. 2012, Sadun et al. 2012), no drug-related adverse events were reported [1, 2, 7].

In the Phase 3 MOVE-FA trial and its long-term extension, vatiquinone continued to demonstrate safety and tolerability [9, 10]. No treatment-related serious adverse events were reported. The adverse-event profile was comparable to placebo.

11.2 Long-term safety

The safety database encompasses more than 500 patients with treatment durations of up to 10 years [10]. This represents one of the most extensive safety databases for a compound in the mitochondrial disease therapeutic space. No treatment-related serious adverse events have been reported in key long-term studies.

11.3 Drug-drug interaction safety

Formal drug-drug interaction studies have characterized the CYP3A4 victim interaction profile [20]. The 3.5-fold increase in exposure with strong CYP3A4 inhibitors represents a potential safety concern in patients receiving concurrent azole antifungals, protease inhibitors, or macrolide antibiotics, as supratherapeutic exposures could alter the benefit-risk profile. Dose adjustment guidance in the context of CYP3A4 inhibitors has been established.

11.4 Pregnancy and lactation

Data on the use of vatiquinone in pregnancy and lactation are not available. The compound has not been evaluated in reproductive toxicology studies in publicly available literature. Given the lipophilic nature and the expected tissue distribution, use in pregnancy should be approached with caution.

11.5 Pediatric safety

The compound has been administered to children as young as 1 year of age in the Leigh syndrome studies and to children aged 7 years and older in the MOVE-FA trial [2, 8]. The pediatric safety profile has been favorable, with no age-specific safety signals identified.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five alternative mitochondrial cytoprotectant or antioxidant compounds against EPI-743, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected as the principal compounds with substantive clinical or preclinical pharmacology programs addressing oxidative stress and mitochondrial dysfunction in the same disease spectrum as EPI-743.

12.1 Idebenone

Mechanism: Idebenone is a synthetic short-chain analog of coenzyme Q10 (2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone) that functions as a mobile electron carrier in the mitochondrial respiratory chain, transferring electrons directly from cytoplasmic NADH to complex III and bypassing a dysfunctional complex I [26]. Unlike EPI-743, idebenone does not selectively inhibit 15-lipoxygenase and does not have a characterized role in glutathione replenishment at clinical concentrations.

Development trajectory: Idebenone was developed by Takeda and subsequently by Santhera Pharmaceuticals for Leber hereditary optic neuropathy (LHON) and Friedreich ataxia. In the RHODOS trial (Klopstock et al. 2011), idebenone 900 mg daily for 24 weeks did not meet its primary endpoint (best recovery in visual acuity) in LHON but showed benefit in a subgroup of patients with discordant visual acuity [27]. The compound received conditional marketing authorization in the European Union for LHON under the trade name Raxone in 2015. Santhera's Friedreich ataxia program (MICONOS trial) failed to demonstrate efficacy at the studied doses and was discontinued [28].

Novelty: Low. The compound has been studied for over three decades and represents conventional quinone-based electron transfer pharmacology.

Effect size: Modest in LHON (subgroup-driven); negative in Friedreich ataxia at studied doses.

Promising potential: Moderate. The compound holds EU conditional approval for LHON but has not achieved US FDA approval and has failed in Friedreich ataxia.

Side-effect profile: Generally well tolerated; gastrointestinal adverse events (nausea, diarrhea) are the most common. No serious safety concerns at registered doses.

Overall validation: Moderate. The EU conditional approval for LHON represents meaningful, if limited, regulatory validation. The Friedreich ataxia failure limits the broader applicability.

Comparison to EPI-743: Idebenone and EPI-743 share the quinone scaffold but differ fundamentally in mechanism. Idebenone bypasses complex I dysfunction; EPI-743 inhibits 15-LO and augments glutathione. EPI-743 has a stronger early signal in LHON (arrest and reversal in 4 of 5 patients vs. subgroup benefit for idebenone) but lacks the regulatory validation (EU approval) that idebenone has achieved. The two compounds are mechanistically complementary rather than competitive.

12.2 Omaveloxolone (Skyclarys)

Mechanism: Omaveloxolone is a semi-synthetic triterpenoid that activates the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor by inhibiting the Keap1-dependent ubiquitination and proteasomal degradation of Nrf2. Nrf2 activation upregulates a battery of endogenous antioxidant and cytoprotective genes including heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and the glutamate-cysteine ligase catalytic subunit [29].

Development trajectory: Omaveloxolone was developed by Reata Pharmaceuticals (now Biogen) for Friedreich ataxia. The MOXIe trial, a randomized, double-blind, placebo-controlled Phase 2 trial, demonstrated a statistically significant benefit on the mFARS at 48 weeks (treatment difference of 2.40 points, $p = 0.014$) [30]. The FDA approved omaveloxolone (Skyclarys) for the treatment of Friedreich ataxia in adults and adolescents aged 16 years and older in February 2023, making it the first FDA-approved treatment for this disease [29].

Novelty: Moderate. The Nrf2 activation mechanism is well characterized but its clinical application in Friedreich ataxia was novel.

Effect size: Modest but statistically significant (mFARS treatment difference of 2.40 points at 48 weeks in the MOXIe trial) [30].

Promising potential: High. The compound is the first and only FDA-approved treatment for Friedreich ataxia. Commercial availability through Biogen.

Side-effect profile: The principal adverse events include elevated aminotransferases, headache, nausea, abdominal pain, fatigue, and diarrhea. Hepatotoxicity monitoring is required per the prescribing label.

Overall validation: High. FDA-approved with a positive Phase 2 trial.

Comparison to EPI-743: Omaveloxolone has achieved regulatory approval for Friedreich ataxia, the primary indication that vatiquinone targeted but for which it received a Complete Response Letter. The mFARS effect sizes are comparable (2.40 for omaveloxolone at 48 weeks; 2.31 for vatiquinone per-protocol at 72 weeks), though the trial designs and patient populations differ. The mechanisms are complementary: omaveloxolone upregulates endogenous antioxidant defenses through Nrf2; vatiquinone directly inhibits 15-LO and replenishes glutathione through NQO1. Omaveloxolone requires hepatotoxicity monitoring; vatiquinone has demonstrated a cleaner safety profile in long-term studies.

12.3 Coenzyme Q10 (Ubiquinone)

Mechanism: Coenzyme Q10 (CoQ10, ubiquinone) is the endogenous mobile electron carrier of the mitochondrial respiratory chain, accepting electrons from complexes I and II and transferring them to complex III. Exogenous CoQ10 supplementation is intended to bypass partial defects in CoQ10 biosynthesis or to augment respiratory chain electron transfer in conditions of increased oxidative phosphorylation demand [31].

Development trajectory: CoQ10 has been evaluated in multiple small clinical trials in mitochondrial diseases and Friedreich ataxia, typically in combination with vitamin E. A randomized trial in 10 Friedreich ataxia patients using CoQ10 (400 mg/day) and vitamin E (2,100 IU/day) for 6 months showed improvements in bioenergetic parameters (reduced lactate rise during exercise) but no consistent neurological or echocardiographic benefits [31]. Glover et al. (2010) conducted a randomized trial of CoQ10 in mitochondrial disorders with modest bioenergetic but minimal clinical improvement [32].

Novelty: Low. The compound is an endogenous metabolite with decades of supplementation research.

Effect size: Small and inconsistent in published clinical trials.

Promising potential: Low as a monotherapy for mitochondrial disease or Friedreich ataxia. The compound remains widely used as an adjunctive nutritional supplement.

Side-effect profile: Excellent. CoQ10 is generally recognized as safe at supplementation doses up to 2,400 mg daily. Gastrointestinal discomfort at high doses is the most common adverse event.

Overall validation: Low. No regulatory approval for any mitochondrial disease indication. Extensive supplementation literature with minimal clinical validation.

Comparison to EPI-743: EPI-743 was identified specifically because it exceeded the cytoprotective potency of CoQ10 by 1,000- to 10,000-fold in the BSO-induced death assay [1]. CoQ10 functions as an electron carrier; EPI-743 inhibits 15-LO and augments glutathione. CoQ10 has the advantage of wide availability, safety, and low cost; EPI-743 has the advantage of potency and mechanism specificity.

12.4 Elamipretide (SS-31, Bendavia, MTP-131)

Mechanism: Elamipretide is a mitochondria-targeted tetrapeptide (D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH₂) that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae architecture and improving electron transport chain efficiency. The compound does not function as an antioxidant per se but rather as a structural stabilizer of the mitochondrial inner membrane [33].

Development trajectory: Stealth BioTherapeutics advanced elamipretide through clinical trials in primary mitochondrial myopathy (the MMPOWER trials), Barth syndrome, and heart failure. The MMPOWER-3 Phase 3 trial in primary mitochondrial myopathy did not meet its primary endpoint (6-minute walk test distance) [34]. The compound received an FDA complete response letter for primary mitochondrial myopathy. Development continues in Barth syndrome and in additional indications.

Novelty: High. The cardiolipin-binding mechanism is fundamentally distinct from quinone-based and Nrf2-based approaches.

Effect size: Modest in Phase 2 trials; Phase 3 negative for primary endpoint in mitochondrial myopathy.

Promising potential: Moderate. The mechanism remains of high scientific interest despite the negative Phase 3 outcome. Active development in Barth syndrome.

Side-effect profile: Generally well tolerated. Injection site reactions (subcutaneous formulation) are the most common adverse events.

Overall validation: Low to moderate. Mechanistically novel but clinically unvalidated at the Phase 3 level in mitochondrial disease.

Comparison to EPI-743: Elamipretide and EPI-743 address different nodes of mitochondrial pathophysiology: elamipretide stabilizes the mitochondrial inner membrane, while EPI-743 inhibits downstream lipid peroxidation. Both compounds have received FDA complete response letters in their lead indications, and neither has achieved regulatory approval. The mechanisms are complementary, and combination research is theoretically justified.

12.5 Alpha-tocopherol (Vitamin E)

Mechanism: Alpha-tocopherol is the most biologically active form of vitamin E and functions as a lipid-soluble radical-trapping antioxidant, terminating lipid peroxidation chain reactions by donating a hydrogen atom to lipid peroxy radicals in cellular membranes [35].

Development trajectory: Vitamin E supplementation has been evaluated in numerous clinical trials in mitochondrial diseases, Friedreich ataxia, and neurodegenerative diseases, typically in combination with coenzyme Q10 or other antioxidants. No randomized controlled trial has demonstrated clinically meaningful neurological benefit from vitamin E supplementation alone in any of these conditions.

Novelty: None. The compound is the historical reference antioxidant.

Effect size: Minimal or absent in controlled clinical trials for mitochondrial disease and Friedreich ataxia.

Promising potential: Low as a monotherapy. The compound is inexpensive and widely available.

Side-effect profile: Generally well tolerated. High-dose supplementation (greater than 400 IU/day) has been associated in meta-analyses with a small increase in all-cause mortality, though this finding is debated.

Overall validation: Low for mitochondrial disease indications. No regulatory approval.

Comparison to EPI-743: EPI-743 is derived from the alpha-tocotrienol form of vitamin E but is the oxidized para-benzoquinone rather than the reduced chromanone. The structural modification converts a radical-trapping antioxidant (alpha-tocotrienol/tocopherol) into a selective 15-LO inhibitor and NQO1 substrate with qualitatively different pharmacology and three to four orders of magnitude greater potency in oxidative stress protection [1]. Alpha-tocopherol scavenges radicals non-selectively after they form; EPI-743 prevents the enzymatic generation of the lipid hydroperoxides upstream. The relationship is one of structural derivation but mechanistic divergence.

12.6 Comparator summary

The five comparators occupy distinct positions in the mitochondrial cytoprotectant and antioxidant pharmacology space. **Idebenone** is a CoQ10 analog that bypasses complex I dysfunction and holds EU conditional approval for LHON but has failed in Friedreich ataxia. **Omaveloxolone** is the only FDA-approved treatment for Friedreich ataxia, acting through Nrf2 upregulation of endogenous antioxidant genes, but carries hepatotoxicity risk. **Coenzyme Q10** is the endogenous electron carrier with wide availability and safety but minimal clinical efficacy as a monotherapy. **Elamipretide** is a cardiolipin-binding peptide with a novel mechanism but a negative Phase 3 outcome. **Alpha-tocopherol** is the historical radical-trapping antioxidant with no demonstrated clinical efficacy in this disease space.

EPI-743 occupies a unique position as a first-in-class selective 15-lipoxygenase inhibitor with NQO1-dependent glutathione replenishment activity. It is the only compound in this panel that specifically targets the enzymatic generation of lipid hydroperoxides rather than scavenging them after formation or broadly upregulating antioxidant gene expression. Its clinical evidence base is stronger than that of coenzyme Q10, elamipretide, and alpha-tocopherol in terms of open-label clinical signals across multiple mitochondrial diseases, but it has not achieved the regulatory validation of omaveloxolone (FDA approval) or idebenone (EU conditional approval). The long-term safety profile (more than 500 patients, up to 10 years, no

treatment-related serious adverse events) is the most favorable in the panel. The pivotal MOVE-FA trial's failure to meet its primary endpoint in the intent-to-treat population, despite positive signals in per-protocol and subscale analyses, and the subsequent FDA complete response letter, represent the principal limitation of the current clinical evidence base.

The principal question for the positioning of EPI-743 is whether the additional clinical study required by the FDA will produce the confirmatory efficacy data needed for approval, and whether the mechanism (15-LO inhibition, glutathione replenishment) will prove to be disease-modifying in controlled studies with adequate statistical power. The existing evidence, taken together with the favorable safety profile and the complementary mechanism relative to omaveloxolone, supports continued clinical development.

13. References

1. Enns GM, Kinsman SL, Perlman SL, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. *Mol Genet Metab.* 2012;105(1):91-102.
2. Martinelli D, Catteruccia M, Piemonte F, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease--genetically defined Leigh Syndrome. *Mol Genet Metab.* 2012;107(3):383-388.
3. Shrader WD, Amagata A, Barnes A, et al. Alpha-tocotrienol quinone modulates oxidative stress response and the biochemistry of aging. *Bioorg Med Chem Lett.* 2011;21(12):3693-3698.
4. Mayer S, Sachse A, Sickert M, et al. Total synthesis of chromanone-based natural products including alpha-tocotrienol quinone. *Synlett.* 2012;23(10):1505-1509.
5. Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. *Nat Chem Biol.* 2017;13(1):81-90.
6. Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. *Cell.* 2017;171(2):273-285.
7. Sadun AA, Chicani CF, Ross-Cisneros FN, et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. *Arch Neurol.* 2012;69(3):331-338.
8. PTC Therapeutics. MOVE-FA trial design and enrollment. *ClinicalTrials.gov* Identifier: NCT04577352.
9. PTC Therapeutics. PTC Therapeutics announces topline results from vatiquinone MOVE-FA registration-directed trial. Press release. 2023.
10. PTC Therapeutics. PTC Therapeutics announces positive results from long-term treatment studies and updates on regulatory progress for vatiquinone Friedreich ataxia program. Press release. October 2024.

11. FDA denies approval for Friedreich ataxia agent vatiquinone, citing more efficacy needed. NeurologyLive. 2025.
12. Sadun AA, La Morgia C, Carelli V. EPI-743 for Leber hereditary optic neuropathy: long-term compassionate use. Invest Ophthalmol Vis Sci. 2015;56(7):Abstract 2145804.
13. BioElectron Technology Corporation (formerly Edison Pharmaceuticals). Corporate updates and clinical trial summaries. MitoAction presentations, 2017-2018.
14. Friedreich's Ataxia Research Alliance. Vatiquinone (PTC-743) drug development profile. FARA website.
15. Stokes JC, Bornstein RL, Manalang GF, et al. Evaluating the efficacy of vatiquinone in preclinical models of Leigh syndrome and GPX4 deficiency. Orphanet J Rare Dis. 2025;20(1):67.
16. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-1072.
17. Gorman GS, Chinnery PF, DiMauro S, et al. Mitochondrial diseases. Nat Rev Dis Primers. 2016;2:16080.
18. Ette EI, Lee SH, Gidal BE, et al. Characterizing population pharmacokinetics of vatiquinone in healthy volunteers and patients with Friedreich's ataxia. Clin Pharmacol Ther. 2025.
19. Ren S, Guo Y, Lee SH, et al. Absorption, distribution, metabolism and excretion of ¹⁴C-vatiquinone in rats, dogs, and human subjects. Xenobiotica. 2023;53(8):493-504.
20. Lee SH, Ren S, et al. Effect of itraconazole, a CYP3A4 inhibitor, and rifampin, a CYP3A4 inducer, on the pharmacokinetics of vatiquinone. Clin Pharmacol Drug Dev. 2024;13(11):1329-1337.
21. Lee SH, Suchowersky O, et al. Clinical drug-drug interaction between vatiquinone, a 15-lipoxygenase inhibitor, and rosuvastatin, a breast cancer resistance protein substrate. Clin Pharmacol Ther. 2023;113(1):175-183.
22. Lee SH, et al. Determination of vatiquinone drug-drug interactions, as CYP450 perpetrator and victim, using physiologically based pharmacokinetic (PBPK) modeling and simulation. J Clin Pharmacol. 2025;65(5):654-665.

23. Yamada K, Toribe Y, Yanagihara K, et al. Japanese Leigh syndrome case treated with EPI-743. *Brain Dev.* 2017;39(9):804-807.
24. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. *Science.* 1996;271(5254):1423-1427.
25. Enns GM, Cohen BH. Clinical trials in mitochondrial disease: an update on EPI-743 and RP103. *J Inborn Errors Metab Screen.* 2017;5:e20170011.
26. Haefeli RH, Erb M, Gemperli AC, et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. *PLoS One.* 2011;6(3):e17963.
27. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. *Brain.* 2011;134(Pt 9):2677-2686.
28. Meier T, Perlman SL, Rummey C, et al. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. *J Neurol.* 2012;259(2):284-291.
29. Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol.* 2021;20(5):339-347.
30. Lynch DR, Chin MP, Boesch S, et al. Efficacy of omaveloxolone in Friedreich's ataxia: delayed-start analysis of the MOXIe extension. *Mov Disord.* 2023;38(2):313-320.
31. Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. *Ann Neurol.* 2001;49(5):590-596.
32. Glover EI, Martin J, Maher A, et al. A randomized trial of coenzyme Q10 in mitochondrial disorders. *Muscle Nerve.* 2010;42(5):739-748.
33. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. *Br J Pharmacol.* 2014;171(8):2029-2050.

34. Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. *Neurology*. 2018;90(14):e1212-e1221.
35. Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. *Free Radic Biol Med*. 2007;43(1):4-15.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. EPI-743 (vatiquinone) is not approved by the United States Food and Drug Administration or by any other regulatory authority. Investigators should consult their local regulatory authority before any human research application.